16 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Alizadeh, Medical Oncologist in Stanford, CA?
Dr. Arash Alizadeh, MD, PHD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. He has been practicing for over 16 years and is board certified. Dr. Alizadeh completed his residency at Stanford University School of Medicine - Stem Cell Institute Dr Weissman's Laboratory. Dr. Alizadeh is fluent in English and Persian, and is currently seeing new patients. Dr. Alizadeh’s practice accepts Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Alizadeh’s office at (650) 498-6000.
Where did Dr. Alizadeh go to medical school and complete their residency?
Fellowship: Stanford University School of Medicine,Stanford, Ca, United States
Residency: Stanford University School of Medicine - Stem Cell Institute Dr Weissman's Laboratory
Is Dr. Alizadeh board certified as a Medical Oncologist?
Yes, Dr. Arash Alizadeh, MD, PHD is board certified by the American Board of Internal Medicine since 2009
What languages does Dr. Alizadeh speak?
Dr. Alizadeh and their clinical team can communicate with patients in the following languages:
English
Persian
What conditions does a Medical Oncologist like Dr. Alizadeh typically treat?
As a Medical Oncologist, Dr. Alizadeh diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Alizadeh. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Diffuse Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Lymphoma
- DLBCL
- Aggressive B-cell Lymphoma
- Diffuse B-cell Lymphoma
- MCL
- Mantle Cell Lymphoma Cancer
- Lymphatic Cancer
- Lymphosarcoma
- NHL
- Follicular Non-Hodgkin Lymphoma
- FL
- Nodular Lymphoma
- Follicular Lymphatic Cancer
- Indolent Lymphoma
ICD-10 Codes:
- C8330: Diffuse large B-cell lymphoma, unspecified site
- C8310: Mantle cell lymphoma, unspecified site
- C8580: Other specified types of non-Hodgkin lymphoma, unspecified site
- C8290: Follicular lymphoma, unspecified, unspecified site
- C8200: Follicular lymphoma grade I, unspecified site
What procedures does a Medical Oncologist like Dr. Alizadeh typically perform?
As a Medical Oncologist, procedures performed by Dr. Arash Alizadeh may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
Please contact Dr. Alizadeh's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Alizadeh accept my insurance?
Dr. Alizadeh accepts most major insurance plans. Important: Please call our office at (650) 498-6000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Alizadeh accept in Stanford, CA?
Dr. Alizadeh in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
AllCare Health
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Hill Physicians Medical Group
Medicare
Santa Cruz County
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Alizadeh's office located?
Recognitions
Publications
Association of a Leukemic Stem Cell Gene Expression Sigture With Clinical Outcomes
, 2010
Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma
, 2009
SOURCE: a unified genomic resource of functiol annotations, ontologies, and gene expression data
, 2003
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
, 2000
The lymphochip: A specialized cD microarray for the genomic
, 1999
High PD-1 expression
, 2013
Germil centre protein HGAL promotes lymphoid hyperplasia
, 2013
Hierarchy in Somatic Mutations Arising During Genomic Evolution
Identification of Candidate Transcriptiol Biomarkers Associated with Chronic Graft-Versus
Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies
Cell-free D as a Biomarker of Residual Disease Following Radiation Therapy for Non
, 2012
CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T
, 2012
The chemoattractant chemerin suppresses melanoma by recruiting tural killer cell antitumor defenses
, 2012
The chemoattractant chemerin as a tural tumor suppressive cytokine.
The CD47-sigl regulatory protein alpha
, 2012
First Isolation of Cryptococcus uzbekistanensis from an Immunocompromised Patient with Lymphoma
, 2012
Three differentiation states risk-stratify bladder cancer into distinct subtypes
, 2012
Treatment advances have not improved the early death rate in acute promyelocytic leukemia
, 2012
Correction: Specific post
, 2012
Specific post-translatiol histone modifications of neutrophil extracellular traps as immunogens
, 2012
Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Prelimiry Results
, 2011
A few good genes Simple, biologically motivated sigtures for cancer prognosis
, 2011
Utility of positron emission tomography scans in mantle cell lymphoma
, 2011
Impact of TET2 mutations on mR expression
, 2011
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3
, 2011
Therapeutic Antibody Targeting of CD47 Elimites Human Acute Lymphoblastic Leukemia
, 2011
Calreticulin Is the Domint Pro-Phagocytic Sigl on Multiple Human Cancers
, 2010
NF-kappa B Sigling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome
, 2010
Second-line mitoxantrone, etoposide
, 2010
B-cell sigling networks reveal a negative prognostic human lymphoma cell subset that emerges during
, 2010
Gene Expression Sigture of Host Immune Response
, 2009
A pluripotency sigture predicts histological transformation
Evaluation and magement of angioimmunoblastic T-cell lymphoma
, 2008
Double trouble in follicular lymphoma: A rare and unusual synergy of oncogenes in the germil center
, 2008
Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan
, 2007
Distinct IL-4-induced gene expression, proliferation
, 2005
AID is expressed in germil center B-cell-like
, 2004
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes
, 2004
Gene expression sigture of fibroblast serum response predicts human cancer progression
, 2004
T cell receptor-independent basal sigling via Erk and Abl kises suppresses RAG gene expression
, 2003
T cell receptor-independent basal sigling via Erk and Abl kises suppresses RAG gene expression.
, 2003
Individuality and variation in gene expression patterns in human blood
, 2003
Molecular heterogeneity in acute rel allograft rejection identified by D microarray profiling
, 2003
Software tools for high-throughput alysis
, 2002
Genomic expression programs and the integration of the CD28 costimulatory sigl in T cell activation
, 2002
Transformation of follicular lymphoma to diffuse large-cell lymphoma
, 2002
The t(14;18) defines a unique subset of diffuse large B
, 2002
Stereotyped and specific gene expression programs in human inte immune responses to bacteria
, 2002
Relation of gene expression phenotype to immunoglobulin mutation genotype
, 2001
Towards a novel classification of human maligncies based on gene expression patterns
, 2001
Genomic alysis of rel allograft dysfunction using cD microarrays
, 2001
Ongoing immunoglobulin somatic mutation in germil center B cell-like but not in activated B cell
, 2000
Exploring gene expression sigtures of host responses to infection
, 2000
Examining the living genome in health and disease with D microarrays
, 2000
Genomic-scale gene expression profiling of normal and malignt immune cells
, 2000
Gene expression in large B-cell lymphoma using cD microarray technology.
, 1999
Genome-wide alysis of D copy-number changes using cD microarrays
, 1999
Probing lymphocyte biology by genomic-scale gene expression alysis
, 1998
Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes
, 2010
Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B
, 2010
CD47 Is an Adverse Prognostic Factor
, 2009
Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma
, 2009
SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data
, 2003
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
, 2000
The lymphochip: A specialized cDNA microarray for the genomic
, 1999
Identification of gene microarray expression profiles in patients with chronic graft-versus
, 2013
Utility in prognostic value added by molecular profiles for diffuse large B-cell lymphoma.
, 2013
Rituximab use and survival after diffuse large B-cell or follicular lymphoma
, 2013
Hierarchy in somatic mutations arising during genomic evolution
, 2013
High PD-1 expression
, 2013
Germinal centre protein HGAL promotes lymphoid hyperplasia
, 2013
Hierarchy in Somatic Mutations Arising During Genomic Evolution
Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell
Genome-Wide Characterization of Human Hematopoietic Progenitor Cell Heterogeneity by Expression
Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus
Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies
Self-antigen recognition by follicular lymphoma B-cell receptors
, 2012
Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non
, 2012
Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma
, 2012
CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T
, 2012
The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor
, 2012
A retrospective study evaluating the efficacy
, 2012
The chemoattractant chemerin as a natural tumor suppressive cytokine.
The CD47-signal regulatory protein alpha
, 2012
First Isolation of Cryptococcus uzbekistanensis from an Immunocompromised Patient with Lymphoma
, 2012
Three differentiation states risk-stratify bladder cancer into distinct subtypes
, 2012
Treatment advances have not improved the early death rate in acute promyelocytic leukemia
, 2012
Correction: Specific post
, 2012
Specific post-translational histone modifications of neutrophil extracellular traps as immunogens
, 2012
Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results
, 2011
A few good genes Simple, biologically motivated signatures for cancer prognosis
, 2011
A proteomic approach for the identification of novel lysine methyltransferase substrates
, 2011
Utility of positron emission tomography scans in mantle cell lymphoma
, 2011
Impact of TET2 mutations on mRNA expression
, 2011
Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia
, 2011
Prediction of survival in diffuse large B
, 2011
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3
, 2011
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
, 2011
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
, 2011
Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers
, 2010
NF-kappa B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome
, 2010
Prediction of Survival In Diffuse Large B
, 2010
Noninvasive Prediction of Graft-Verus
, 2010
Self-Antigen Recognition by the B Cell Receptors of Follicular Lymphoma
, 2010
Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14
, 2010
Second-line mitoxantrone, etoposide
, 2010
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges
, 2010
Expression profiles of adult T-cell leukemia-lymphoma
, 2010
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
, 2010
Noninvasive Prediction of Graft-Versus
, 2010
Is Time of the Essence in Adult Acute Myeloid Leukemia
, 2010
Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B
, 2009
Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient
, 2009
Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes
, 2009
Is Time of the Essence in Adult Acute Myeloid Leukemia
, 2009
Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
, 2009
A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma
, 2009
Therapeutic Potential of Anti-CD137 Antibody in Lymphoma
, 2009
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion
, 2009
CD47 IS AN ADVERSE PROGNOSTIC FACTOR IN NON
, 2009
A pluripotency signature predicts histological transformation
Evaluation and management of angioimmunoblastic T-cell lymphoma
, 2008
CD47 Is An Independent Prognostic Factor
, 2008
LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B
, 2008
Double trouble in follicular lymphoma
, 2008
Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan
, 2007
Cell-type specific gene expression profiles of leukocytes in human peripheral blood
, 2006
Distinct IL-4-induced gene expression, proliferation
, 2005
AID is expressed in germinal center B-cell-like
, 2004
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53
, 2004
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes
, 2004
Gene expression signature of fibroblast serum response predicts human cancer progression
, 2004
Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock
, 2004
T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression
, 2003
T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression.
, 2003
Rheumatoid arthritis is a heterogeneous disease
, 2003
Transformation of follicular lymphoma to diffuse large cell lymphoma is
, 2003
Individuality and variation in gene expression patterns in human blood
, 2003
HGAL is a novel interleukin-4
, 2003
Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling
, 2003
Software tools for high-throughput analysis
, 2002
Genomic expression programs
, 2002
Transformation of follicular lymphoma to diffuse large-cell lymphoma
, 2002
The t(14;18) defines a unique subset of diffuse large B
, 2002
In vivo regulation of human skeletal muscle gene expression by thyroid hormone
, 2002
Stereotyped and specific gene expression programs in human innate immune responses to bacteria
, 2002
Relation of gene expression phenotype to immunoglobulin mutation genotype
, 2001
Towards a novel classification of human malignancies based on gene expression patterns
, 2001
Genomic analysis of renal allograft dysfunction using cDNA microarrays
, 2001
Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell
, 2000
Exploring gene expression signatures of host responses to infection
, 2000
Examining the living genome in health and disease with DNA microarrays
, 2000
Genomic-scale gene expression profiling of normal and malignant immune cells
, 2000
'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns.
, 2000
Gene expression in large B-cell lymphoma using cDNA microarray technology.
, 1999
Genome-wide analysis of DNA copy-number changes using cDNA microarrays
, 1999
Probing lymphocyte biology by genomic-scale gene expression analysis
, 1998
What is Dr. Alizadeh's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Alizadeh's National Provider Identifier (NPI) number is 1295824423.
What common questions do patients ask about Dr. Alizadeh?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Alizadeh
What is Dr. Arash Alizadeh's specialty?
Dr. Alizadeh is a Medical Oncologist near Stanford, CA.
What does a Medical Oncologist do?
An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options.
Is this Dr. Arash Alizadeh affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Alizadeh is affiliated with Stanford Health Care - Stanford Hospital, Stanford Health Care - Valleycare, Renown Regional Medical Center which are a Castle Connolly Top Hospitals. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Medical Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Medical Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Arash Alizadeh accepting new patients in Stanford, CA?
Yes, Dr. Arash Alizadeh is accepting new patients at this time.
Does Dr. Arash Alizadeh offer online booking?
Please contact Dr. Alizadeh's office at (650) 498-6000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Arash Alizadeh?
Please contact Dr. Alizadeh's office at (650) 498-6000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Arash Alizadeh have?
Dr. Arash Alizadeh is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patients
Medical Oncologist
Accepting patients